20:23 , Nov 3, 2017 |  BC Week In Review  |  Financial News

BioGeneration closes Ventures Fund III at EUR82M

On Oct. 31, BioGeneration Ventures announced the final close of BioGeneration Ventures Fund III at €82 million ($95.3 million). The fund's LPs included two strategic investors, Bristol-Myers Squibb Co. (NYSE:BMY) and Johnson & Johnson Innovation...
21:37 , Nov 2, 2017 |  BioCentury  |  Finance

Bigger in Benelux

BioGeneration Ventures parlayed two major wins from its second fund into its largest fund to date, and now has the capital reserves for follow-on investments so the firm can retain more value in portfolio companies....
00:01 , Oct 31, 2017 |  BC Extra  |  Financial News

BioGeneration closes third fund

European VC BioGeneration Ventures announced the final close of BioGeneration Ventures Fund III at €82 million ($95.3 million). The fund's LPs included two strategic investors, Bristol-Myers Squibb Co. (NYSE:BMY) and Johnson & Johnson Innovation --...
21:42 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Amgen discontinues development of CETP inhibitor

Amgen Inc. (NASDAQ:AMGN) discontinued internal development of cholesteryl ester transfer protein (CETP) inhibitor AMG 899 (TA-8995). The company said it will explore out-licensing of the product, which it gained via its 2015 acquisition of Dezima...
23:42 , Oct 25, 2017 |  BC Extra  |  Company News

Amgen raises guidance, discontinues CETP inhibitor

In its 3Q17 earnings late Wednesday, Amgen Inc. (NASDAQ:AMGN) bumped up its 2017 guidance and said it discontinued internal development of cholesteryl ester transfer protein inhibitor AMG 899 . The bellwether pushed its 2017 non-GAAP...
21:14 , Oct 13, 2017 |  BC Week In Review  |  Clinical News

End of the road for Merck's anacetrapib

Merck & Co. Inc. (NYSE:MRK) said it will not seek regulatory approval of anacetrapib (MK-0859) to treat coronary heart disease (CHD). Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Although anacetrapib met the primary...
19:37 , Oct 12, 2017 |  BC Extra  |  Clinical News

End of the road for Merck's anacetrapib

Merck & Co. Inc. (NYSE:MRK) said it will not seek regulatory approval of anacetrapib (MK-0859) to treat coronary heart disease (CHD). Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Although anacetrapib met the primary...
19:56 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

Merck reports additional data for CETP inhibitor in CHD

Merck & Co. Inc. (NYSE:MRK) reported additional data from the Phase III REVEAL trial in patients with atherosclerotic vascular disease showing that once-daily 100 mg oral anacetrapib (MK-0859) reduced major coronary events -- the primary...
23:56 , Aug 29, 2017 |  BC Extra  |  Clinical News

Merck's CETP inhibitor may miss the mark for CV benefit

Merck & Co. Inc. (NYSE:MRK) reported additional data from the Phase III REVEAL cardiovascular outcomes trial showing that anacetrapib (MK-0859) reduced major coronary events -- the primary endpoint defined as a composite of coronary death,...
21:57 , Jul 7, 2017 |  BioCentury  |  Product Development

One small CETP for Merck

Merck & Co. Inc. ’s massive cardiovascular outcomes trial for anacetrapib finally may have shown a CETP inhibitor provides a benefit. But the question remains whether the relative risk reduction is large enough for it...